$GALE: Wow, did you see the 8K for GALE? Galena
Post# of 23114
(Total Views: 271)
Posted On: 10/02/2017 3:00:51 PM
$GALE: Wow, did you see the 8K for GALE?
Galena Biopharma Files 8K - Other Events GALE
10:08 AM ET 10/2/17 | Dow Jones
Galena Biopharma Inc. (GALE) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on October 02, 2017.
On October 2, 2017, SELLAS Life Sciences Group Ltd ("SELLAS"
issued a press release entitled "SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. , Kenilworth, N.J., USA." A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/139047...739d8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/139047...-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
Galena Biopharma Files 8K - Other Events GALE
10:08 AM ET 10/2/17 | Dow Jones
Galena Biopharma Inc. (GALE) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on October 02, 2017.
On October 2, 2017, SELLAS Life Sciences Group Ltd ("SELLAS"
issued a press release entitled "SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. , Kenilworth, N.J., USA." A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/139047...739d8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/139047...-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
(1)
(0)